Anika Therapeutics Inc
ANIK9.546USD
-0.024-0.25%
Market hours （ET）Quotes delayed by 15 min
137.67MMarket Cap
LossP/E TTM
More Details of Anika Therapeutics Inc Company
Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
Anika Therapeutics Inc Info
Ticker SymbolANIK
Company nameAnika Therapeutics Inc
IPO dateMay 16, 1985
CEOBlanchard (Cheryl Renee)
Number of employees288
Security typeOrdinary Share
Fiscal year-endMay 16
Address32 Wiggins Ave
CityBEDFORD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code01730-2315
Phone17814579000
Websitehttps://anika.com/
Ticker SymbolANIK
IPO dateMay 16, 1985
CEOBlanchard (Cheryl Renee)
Company Executives of Anika Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Glenn R. Larsen, Ph.D.
Dr. Glenn R. Larsen, Ph.D.
Independent Director
Independent Director
50.26K
+39.24%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
39.84K
+55.16%
Mr. William R. (Bill) Jellison
Mr. William R. (Bill) Jellison
Independent Director
Independent Director
23.10K
+158.45%
Mr. Joseph H. (Joe) Capper
Mr. Joseph H. (Joe) Capper
Independent Director
Independent Director
20.40K
+227.02%
Mr. Stephen D. (Steve) Griffin
Mr. Stephen D. (Steve) Griffin
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
9.07K
--
Mr. Matt Hall
Mr. Matt Hall
Director, Corporate Development and Investor Relations
Director, Corporate Development and Investor Relations
--
--
Mr. Ian McLeod
Mr. Ian McLeod
Chief Accounting Officer, Vice President, Treasurer
Chief Accounting Officer, Vice President, Treasurer
--
--
Mr. Gary P. Fischetti
Mr. Gary P. Fischetti
Independent Director
Independent Director
--
--
Dr. Cheryl Renee Blanchard, Ph.D.
Dr. Cheryl Renee Blanchard, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David B. Colleran, J.D.
Mr. David B. Colleran, J.D.
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Glenn R. Larsen, Ph.D.
Dr. Glenn R. Larsen, Ph.D.
Independent Director
Independent Director
50.26K
+39.24%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
39.84K
+55.16%
Mr. William R. (Bill) Jellison
Mr. William R. (Bill) Jellison
Independent Director
Independent Director
23.10K
+158.45%
Mr. Joseph H. (Joe) Capper
Mr. Joseph H. (Joe) Capper
Independent Director
Independent Director
20.40K
+227.02%
Mr. Stephen D. (Steve) Griffin
Mr. Stephen D. (Steve) Griffin
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
9.07K
--
Mr. Matt Hall
Mr. Matt Hall
Director, Corporate Development and Investor Relations
Director, Corporate Development and Investor Relations
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
OEM Channel
16.34M
57.90%
Commercial Channel
11.88M
42.10%
By RegionUSD
Name
Revenue
Proportion
United States
17.92M
63.52%
Other
5.54M
19.64%
Europe
4.75M
16.84%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
OEM Channel
16.34M
57.90%
Commercial Channel
11.88M
42.10%
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Trigran Investments, Inc.
11.24%
Caligan Partners, LP
9.95%
BlackRock Institutional Trust Company, N.A.
6.38%
The Vanguard Group, Inc.
5.41%
BlackRock Financial Management, Inc.
5.38%
Other
61.63%
Shareholders
Shareholders
Proportion
Trigran Investments, Inc.
11.24%
Caligan Partners, LP
9.95%
BlackRock Institutional Trust Company, N.A.
6.38%
The Vanguard Group, Inc.
5.41%
BlackRock Financial Management, Inc.
5.38%
Other
61.63%
Shareholder Types
Shareholders
Proportion
Hedge Fund
29.85%
Investment Advisor/Hedge Fund
27.73%
Investment Advisor
25.43%
Individual Investor
4.88%
Research Firm
2.02%
Pension Fund
0.51%
Bank and Trust
0.12%
Venture Capital
0.09%
Other
9.38%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
245
12.37M
97.19%
-666.00
2025Q3
267
12.37M
100.32%
-461.27K
2025Q2
295
12.88M
103.23%
-71.30K
2025Q1
297
12.95M
103.38%
-1.70M
2024Q4
298
12.83M
102.20%
-560.99K
2024Q3
297
13.48M
104.72%
-150.44K
2024Q2
301
13.64M
105.78%
+30.78K
2024Q1
301
13.61M
105.08%
-1.78M
2023Q4
304
13.45M
105.34%
+303.47K
2023Q3
297
13.16M
105.14%
-356.42K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Trigran Investments, Inc.
2.04M
14.12%
-5.34K
-0.26%
Jun 30, 2025
Caligan Partners, LP
1.44M
9.95%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
937.30K
6.5%
-20.13K
-2.10%
Jun 30, 2025
The Vanguard Group, Inc.
779.47K
5.41%
+2.07K
+0.27%
Jun 30, 2025
BlackRock Financial Management, Inc.
546.12K
3.79%
+24.11K
+4.62%
Jun 30, 2025
Acadian Asset Management LLC
575.64K
3.99%
+36.03K
+6.68%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
623.08K
4.32%
+9.11K
+1.48%
Jun 30, 2025
The Capital Management Corporation
408.85K
2.84%
+79.19K
+24.02%
Jun 30, 2025
Boothbay Fund Management, LLC
529.50K
3.67%
--
--
Jun 30, 2025
Renaissance Technologies LLC
527.22K
3.66%
-1.40K
-0.26%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.56%
Royce Quant Small-Cap Quality Value ETF
0.2%
SPDR SSGA US Small Cap Low Volatility Index ETF
0.1%
iShares Micro-Cap ETF
0.02%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
WisdomTree US SmallCap Fund
0.01%
iShares Russell 2000 Value ETF
0.01%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.56%
Royce Quant Small-Cap Quality Value ETF
Proportion0.2%
SPDR SSGA US Small Cap Low Volatility Index ETF
Proportion0.1%
iShares Micro-Cap ETF
Proportion0.02%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.02%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
WisdomTree US SmallCap Fund
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Anika Therapeutics Inc?
The top five shareholders of Anika Therapeutics Inc are:
Trigran Investments, Inc. holds 2.04M shares, accounting for 14.12% of the total shares.
Caligan Partners, LP holds 1.44M shares, accounting for 9.95% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 937.30K shares, accounting for 6.50% of the total shares.
The Vanguard Group, Inc. holds 779.47K shares, accounting for 5.41% of the total shares.
BlackRock Financial Management, Inc. holds 546.12K shares, accounting for 3.79% of the total shares.
Trigran Investments, Inc. holds 2.04M shares, accounting for 14.12% of the total shares.
Caligan Partners, LP holds 1.44M shares, accounting for 9.95% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 937.30K shares, accounting for 6.50% of the total shares.
The Vanguard Group, Inc. holds 779.47K shares, accounting for 5.41% of the total shares.
BlackRock Financial Management, Inc. holds 546.12K shares, accounting for 3.79% of the total shares.
What are the top three shareholder types of Anika Therapeutics Inc?
The top three shareholder types of Anika Therapeutics Inc are:
Trigran Investments, Inc.
Caligan Partners, LP
BlackRock Institutional Trust Company, N.A.
Trigran Investments, Inc.
Caligan Partners, LP
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Anika Therapeutics Inc (ANIK)?
As of 2025Q4, 245 institutions hold shares of Anika Therapeutics Inc, with a combined market value of approximately 12.37M, accounting for 97.19% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -3.13%.
What is the biggest source of revenue for Anika Therapeutics Inc?
In FY2025Q2, the OEM Channel business generated the highest revenue for Anika Therapeutics Inc, amounting to 16.34M and accounting for 57.90% of total revenue.
